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1. Introduction  
Enterococci are intestinal colonizers in many mammals including man, birds, reptiles and 
even invertebrates and are also found in diverse environments such as sewage, soil and 
water. They have been used for decades for food fermentation and preservation due to their 
metabolic properties and their capability to produce bacteriocins active against food 
contaminants like Listeria. Within the last two decades enterocococci became prominent as 
important hospital-acquired pathogens. Isolates of Enterococcus faecalis and E. faecium are the 
third- to fourth-most prevalent nosocomial pathogen worldwide. Among ICU-acquired 
bloodstream infections enterococci ranked second most prevalent according to data from an 
European project on Healthcare-Associated Infections.1 Infections with enterococci hit the 
very young, the elderly and immuno-compromised patients and are thus mostly restricted 
to specific hospital wards like haemato-oncological, paediatric, and intensive care units. The 
growing number of patients at risk of acquiring an enterococcal infection is linked to an 
aging population, especially in industrialised countries, and an increasing application of 
invasive medical treatment options.  
Non-susceptibility to glycopeptide antibiotics like vancomycin and teicoplanin is the key 
resistance characteristic in enterococci. Acquired resistance to vancomycin is mediated by 
various mechanisms (types VanA/B/D/E/G/L; Table 1); the vanA and vanB resistance 
genotypes are by far the most prevalent. The reservoir for vanA- and vanB-type resistance in 
humans is in E. faecium (Christiansen et al., 2004; Willems and van Schaik W. 2009; Johnson 
et al., 2010; Willems et al., 2011). Consequently, increasing rates of VRE in several European 
countries are due to an increasing prevalence of vancomycin-resistant E. faecium (VREfm). 
Ampicillin- and/or vancomycin-resistant E. faecalis (VREfs) are still rare. Defined clonal 
groups of E. faecium show an enhanced capacity to disseminate in the nosocomial setting 
and are thus called epidemic or hospital-acquired (Top et al., 2008a; Willems and van Schaik 
W. 2009; EARSS 2009; Willems et al., 2011). These strains can be assigned to distinct clonal 
groups or complexes based on various molecular typing schemes and subsequent 
phylogenetic analyses (Willems and van Schaik W. 2009; Willems et al., 2011). Hospital-
acquired E. faecium are mostly ampicillin-resistant, partly high-level ciprofloxacin-resistant 
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and possess additional genomic content (accessory genome), which includes putative 
virulence traits such as a gene for an enterococcal surface protein, esp, genes encoding 
different cell wall-anchored surface proteins, a putative hyaluronidase gene, hylEfm and a 
gene encoding a collagen-binding protein, acm (Willems et al., 2001; Leavis et al., 2007; 
Hendrickx et al., 2007; Hendrickx et al., 2008; Heikens et al., 2008; Sillanpaa et al., 2008; 
Nallapareddy et al., 2008; Hendrickx et al., 2009; van Schaik et al., 2010; Laverde Gomez et 
al., 2010; van Schaik and Willems 2010). 
2. Natural antibiotic resistances in E. faecium and E. faecalis  
Besides their huge arsenal of insusceptibilities to physicochemical and environmental 
stresses (Murray 1990; Facklam et al., 2002) E. faecalis and E. faecium possess a broad 
spectrum of natural antibiotic resistances (Klare et al., 2003; Arias and Murray 2008). 
All enterococci are naturally (intrinsically) resistant to the following agents: semisynthetic 
penicillins (e.g., oxacillin), cephalosporins of all classes, monobactams and polymyxins. 
Aminoglycosides show insusceptibility at a low level, most probably due to a reduced 
uptake. At least, isolates of E. faecalis and E. faecium show clindamycin insusceptibility; in E. 
faecalis this is known to be associated with the expression of an ABC porter designated Lsa 
(Singh et al., 2002; Singh and Murray 2005). Presence of Lsa also mediates resistance to 
streptogramin A which in the consequence also leads to resistance to the streptogramin A/B 
combination (quinupristin/dalfopristin). Insusceptibility to fluoroquinolones, for instance to 
ciprofloxacin, is most probably associated with expression of chromosomal qnr homologues 
(functionally proven only for E. faecalis, (Arsene and Leclercq 2007; Rodriguez-Martinez et 
al., 2008). Isolates of E. faecalis are also resistant to mupirocin, a property that can be used to 
differentiate them from other enterococcal species. Although not reaching the level of what 
is defined as resistance, penicillins are generally less active against enterococci than against 
streptococci and in addition, E. faecium is less susceptible than E. faecalis (Murray 1990).  
3. Acquired antibiotic resistances in E. faecium and E. faecalis 
The already tremendous spectrum of intrinsic insusceptibilities of E. faecalis and E. faecium is 
accompanied by the potential to acquire resistance to all antimicrobial drugs available 
(Tenover and McDonald 2005; Rice 2006). Therapeutically important are resistance 
properties against penicllin/ampicillin, gentamicin/streptomycin and glycopeptides 
(vancomycin/teicoplan) as well as resistances against antibiotics of last resort 
quinupristin/dalfopristin [E. faecium], linezolid and tigecycline (maybe also daptomycin). 
3.1 Penicillin resistance 
Penicillin resistance in E. faecalis is rare and if occurring linked to certain clonal lineages 
expressing beta-lactamases similar or identical to the S. aureus penicillinase (Nallapareddy et 
al., 2005; Ruiz-Garbajosa et al., 2006; McBride et al., 2007). Penicillin resistance in E. faecium 
is mediated via point mutations in the housekeeping pbp5 gene leading to reduced penicillin 
binding to the expressed protein (Jureen et al., 2004; Rice et al., 2004; Rice et al., 2009). 
Mutated pbp5’ was also found as an integral part of conjugative transposons, like Tn5382, 
thus encoding transferable ampicillin and VanB-type vancomycin resistance (Carias et al., 
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1998; Valdezate et al., 2009). Results of a recent study suggested additional factors 
independent from pbp5’ contributing to acquired ampicillin resistance in hospital strains of 
E. faecium (Galloway-Pena et al., 2011). 
3.2 Aminoglycoside resistance   
Only the two aminoglycosides gentamicin and streptomycin exemplify a synergistic effect 
when given in combination with a cell-wall active agent like a penicillin or a glycopeptide 
(Murray 1990). Certain aminoglycoside-modifying enzymes mediate acquired high-level 
gentamicin and streptomycin resistance in E. faecalis and E. faecium. The aac6’-aph2’’ (aac(6')-Ie-
aph(2")-Ia) gene encodes a bifunctional enzyme encoding high-level resistance to all 
aminoglycosides except streptomycin (Horodniceanu et al., 1979). It is the most prevalent form 
of acquired gentamicin resistance in both species and associated with homologues of 
transposon Tn4001/Tn5281 flanked by two copies of IS256 and most probably originating 
from staphylococci (Casetta et al., 1998; Hallgren et al., 2003; Saeedi et al., 2004). Gentamicin 
resistance may also be encoded by other determinants such as aac(6')-Ii, aph(2”)-Ie, and ant(6)-
Ia (Jackson et al., 2004; Jackson et al., 2005; Zarrilli et al., 2005; Mahbub et al., 2005). High-level 
streptomycin resistance is encoded by the aadE gene which is an integral part of a multi-
resistance gene cluster aadE-sat4-aphA encoding streptomycin-streptothricin-kanamycin 
resistance. The sat4 gene encoding streptothricin (nourseothricin) resistance has first been 
described in Campylobacter coli (Jacob et al., 1994; Bischoff and Jacob 1996). In staphylococci the 
aadE-sat4-aphA gene cluster is flanked by two copies of IS1182 constituting transposon Tn5405 
(Derbise et al., 1996; Derbise et al., 1997). The aadE-sat4-aphA gene cluster is widespread among 
many Gram-positive genera and it remains to be speculative where this gene clusters 
originates from and subsequently spread to other bacteria. Strikingly, in S. aureus the sat4 gene 
possesses a point mutation within the coding region leading to a pre-mature STOPP codon; 
whereas it is complete and functional in C. coli and enterococci encoding detectable 
streptothricin (nourseothricin) insusceptibility (Schwarz et al., 2001; Werner et al., 2001a; 
Teuber et al., 2003; Werner et al., 2003a). 
3.3 Fluoroquinolone resistance   
The targets of fluoroquinolones are topoisomerases II and IV, and mutational changes 
among genes encoding mainly subunits A and to a lesser extent also subunits B are 
associated with increased MICs to ciprofloxacin and other fluoroquinolones (Hooper 2002; 
Jacoby 2005). Topoisomerase II (DNA gyrase) appears to be the primary target in Gram-
negative bacteria and topoisomerase IV is the primary target in Gram-positive bacteria. 
Corresponding in vitro selection models were also described for enterococci; however, 
results are somehow conflicting regarding the primary target in Enterococcus spp. and the 
necessity of specific mutations in one or both A subunit genes to confer what is specified 
as high-level ciprofloxacin resistance (Onodera et al., 2002; Oyamada et al., 2006a; 
Oyamada et al., 2006b). Molecular studies with high-level ciprofloxacin-resistant clinical 
isolates revealed mutations in both A subunits associated with different levels of 
ciprofloxacin resistance, whereas mutations in gyrB and parE alleles were only 
infrequently found (Woodford et al., 2003; Leavis et al., 2006; Valdezate et al., 2009; 
Werner et al., 2010a). 
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3.4 Resistance to macrolides, lincosamides and streptogramin B (MLSB)  
Resistance to MLSB antibiotics is encoded by the widespread erm(B) gene and only 
occasionally via erm(A) or erm(C)(Roberts et al., 1999). Erm (“erythromycin resistance 
methylases”) confer resistance by modifying nucleotide A2058 of the bacterial 23S rRNA 
(methylation) leading to resistance to MLSB antibiotics. The resistance phenotype is partly 
overlapping with the spectrum of natural resistances in Enterococcus (lincosamides); 
however, erm genes are widespread among other Gram-positive bacteria such as 
streptococci, staphylococci, lactococci and lactobacilli where the corresponding resistance 
phenotype has been studied in detail (Shaw and Clewell 1985; Novick and Murphy 1985). 
Naturally, the expression of erm genes is induced with low levels of 14-membered 
macrolides (i.e. erythromycin) and results in cross-resistance to all 14-, 15- and 16-membered 
macrolides, lincosamides and streptogramin B antibiotics. Induction results from 
translational relief of attenuation (Horinouchi and Weisblum 1980). Constitutive expression 
of erm(A) and erm(C) in staphylococci results from deletions, duplications, and point 
mutations in the region of the leader peptide, and is selected for by the use of non-inducing 
antibiotics (Werckenthin et al., 1999; Werckenthin and Schwarz 2000; Schmitz et al., 2001). In 
enterococci erm(B) is constitutively expressed (Werner et al., 2000; Werner et al., 2002; Martel 
et al., 2003); however, corresponding modifications in the leader peptide could not be linked 
unambiguously to cause the corresponding phenotype in wildtype isolates (Rosato et al., 
1999; Werner et al., 2002). Recent in vitro studies have linked point mutations rather than 
deletions and duplications to a corresponding erm(B) constitutive phenotype in enterococci 
(Min et al., 2008). The erm(B) determinant is widespread among enterococci, especially E. 
faecium and E. faecalis and is part of many multi-resistance plasmids and often linked to 
Tn1546-like vanA elements (Aarestrup et al., 2000a; Borgen et al., 2002; Werner et al., 2003a; 
Werner et al., 2003b; Manson et al., 2003b; Werner et al., 2006; Laverde Gomez et al., 2010). 
Another mechanism mediating macrolide (and streptogramin B) resistance is conferred by 
the msrA-C genes (Reynolds et al., 2003; Kerr et al., 2005) whereas msrC is discussed as a 
species-specific property in E. faecium (Singh et al., 2001; Werner et al., 2001b) shown to 
encode erythromycin and clarithromycin resistance when expressed in S. aureus (Reynolds 
and Cove 2005). Staphylococcal efflux pumps of the Vgb-type encoding for streptogramin 
type B resistance remain extremely rare among E. faecium (Werner et al., 2002).  
3.5 Streptogramin A resistance  
Two types of acetyltransferases VatD and VatE mediate resistance to streptogramin A in 
enterococci, mainly E. faecium (Werner et al., 2002). E. faecalis is naturally resistant to 
streptogramin A and thus the synergism of the A and B streptogramin combination is 
abolished (Werner et al., 2002; Singh et al., 2002). However, a few studies described also vat 
genes to be prevalent among related lactic acid bacteria (Gfeller et al., 2003) and E. faecalis 
isolates (Simjee et al., 2002; Jones and Deshpande 2004). Their relevance for increasing the level 
of streptogramin resistance in E. faecalis is unclear; nevertheless, resistance determinants could 
further spread to E. faecium and other enterococcal species thus rendering their level of 
streptogramin susceptibility. Staphylococcal efflux pumps of the Vga-type encoding for 
streptogramin type A resistance remain unknown to E. faecium (Werner et al., 2002); except for 
a single Korean E. faecium isolate described recently harbouring streptogramin A resistance 
genes vgaD and vatG on a plasmid fragment encoding for a new efflux pump type and a new 
streptogramin acetyltransferase, respectively (Jung et al., 2010). 
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3.6 Tetracycline resistance 
Resistance to tetracyclines is mediated via different acquired tet genes encoding proteins 
mediating (a) ribosomal protection [tet(O)/(M)(S)] or efflux [tet(K)/(L)] [(Roberts 2005). 
Most wide-spread among enterococci and best studied are elements containing tet(M). The 
tet(M) gene mostly resides on conjugative transposons of the Tn916/Tn1545- or Tn5397-
types that possess a very wide host range and can exist in several functional copies thus 
supporting flexibility and recombinational events within a given bacterial genome (Thal et 
al., 1997; Roberts et al., 2001; Agerso et al., 2006; Rice et al., 2007; Boguslawska et al., 2009; de 
Vries et al., 2009; Rice et al., 2010; Roberts and Mullany 2011).  
3.7 Linezolid resistance 
Linezolid is a synthetic oxazolidinone antibiotic of last resort active against multi- and 
vancomycin-resistant enterococci. It inhibits first steps of ribosome formation [108]. 
Although being fully synthetic, resistance is selected under therapy and is in relation to the 
duration of treatment (Prystowsky et al., 2001; Pai et al., 2002; Ruggero et al., 2003; Seedat et 
al., 2006). However, a few reports documented resistance detection independent from 
linezolid treatment (Rahim et al., 2003; Bonora et al., 2006). Resistance results from point 
mutations in 23S rRNA, preferably at position 2576 (G > T)(Sinclair et al., 2003; Werner et al., 
2004; Qi et al., 2006; Werner et al., 2007a) and the level of resistance is dependent on the 
number of mutated alleles per genome (Marshall et al., 2002; Lobritz et al., 2003; Bourgeois-
Nicolaos et al., 2007; Boumghar-Bourtchai et al., 2009). Once established, resistance levels 
quickly arise due to recombinational exchange of mutated 23S rDNA alleles under selective 
pressure (Willems et al., 2003; Boumghar-Bourtchai et al., 2009). In Staphylococcus, a Cfr 
methylase is able to modify 23S rRNA at position A2503 leading to cross-resistance to a 
number of antibiotics including oxazolidinones (Toh et al., 2007); however, the 
corresponding cfr gene has not been described in enterococci so far.  
3.8 Tigecycline resistance 
Tigecycline is a member of a new tetracycline antibiotic class containing a 9-tert-
butylglycylamido group named glycylcyclines and acts similar to tetracyclines by inhibiting 
protein biosynthesis. Tigecycline is active against many Gram-negative and Gram-positive 
bacteria including isolates of Enterococcus. International surveillance studies revealed in 
general potent in vitro activity; non-susceptible isolates are very rare. A single resistance 
mechanism linked to an overexpression of an oxygen- and flavin-dependent 
monooxygenase, TetX, originating from anaerobic bacteria of the genus Bacteroides was 
described (Moore et al., 2005). A single tigecycline-non-susceptible E. faecalis isolate was 
reported recently and investigated in greater details; however, the underlying resistance 
mechanism could not been determined (Werner et al., 2008b).  
3.9 Daptomycin resistance  
Daptomycin is a cyclic lipopeptide antibiotic disrupting cell membrane composition, 
function and permeability (Straus and Hancock 2006a; Straus and Hancock 2006b). 
Daptomycin is active against many Gram-positive bacteria. Its in vivo activity against 
enterococci is still debatable (Canton et al., 2010). Daptomycin resistance developed under 
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therapy in bacteria other than enterococci and was multifactorial and is still not understood 
completely (Fischer et al., 2011).  
3.10 Vancomycin resistance 
Glycopeptide antibiotics consist of a peptide ring to which several sugars are covalently 
linked. They are produced by actinomycetes and have a quite complex structure. This 
voluminous structure prevents penetration through the outer membrane of Gram-negative 
bacteria limiting their therapeutic use only to treat infections with Gram-positive bacteria. 
Two naturally produced antibiotics have been introduced into antimicrobial treatment, 
vancomycin and teicoplanin; the latter only outside North-America. Three semisynthetic 
progenitors designated as lipoglycopeptides or glycolipopeptides (dalbavancin, telavancin, 
oritavancin) are promising new candidate drugs partially active against multi-resistant and 
also vancomycin-(intermediate)resistant bacteria (Zhanel et al., 2010a). The primary target of 
glycopeptides is the C-terminal D-Alanyl-D-Alanine ending of the peptide side chain of the 
enterococcal peptidoglycan cell wall precursor. Due to steric hindrance the cell wall 
synthesis enzymes like transglycosylases, transpeptidases and D,D-carboxypeptidases 
cannot access their target and cell wall synthesis stops. Vancomycin and related 
glycopeptides act as dimers (Batchelor et al., 2010).  
Enterococci were the first pathogens that showed acquired vancomycin resistance and 
corresponding strains have been isolated from clinical samples from patients in Europe and 
the USA in the late 1980s (Leclercq et al., 1988; Leclercq et al., 1989; Sahm et al., 1989). The 
corresponding resistance phenotypes which included inducible resistance to all known 
glycopeptides or vancomycin only were designated VanA and VanB, respectively. In fact, 
the structure, localization and functional interplay of the resistance determinants arranged 
in specific transposable elements in enterococci has been studied with some of the first 
identified VRE: E. faecium BM4147 (vanA genotype) from France (Leclercq et al., 1988) and E. 
faecalis V583 (vanB genotype) from the USA (Sahm et al., 1989). The latter became prominent 
as the first Enterococcus isolate that has been completely sequenced (Paulsen et al., 2003). To 
date eight types of acquired vancomycin resistance in enterocooci are known having a 
related mechanism of resistance and a similar resistance gene cluster composition but show 
major differences in prevalence (Table 1 and Figure 1; see recent reviews for details: 
(Courvalin 2005; Courvalin 2006; Werner et al., 2008a; Werner et al., 2008c). Worldwide by 
far the most prevalent type is vanA followed by vanB. The vanA gene is an integrated part of 
Tn1546 or derivatives of this transposon which are usually located on transferable plasmids 
(Werner et al., 2008a; Werner 2011). vanB could be subdivided into three different allele 
types (vanB1-3) with vanB-2 the most prevalent type worldwide. The vanB alleles are part of 
Tn1547 or the conjugative transposon Tn1549/5382 which are mainly chromosomally located 
and less frequently, on plasmids (Werner et al., 2006; Zheng et al., 2009; Hegstad et al., 2010; 
Bjorkeng et al., 2011). The main clinical relevant reservoir of vanA and vanB elements is in E. 
faecium, at least in Europe, Northern and Latin America and Southeast Asia, although they 
have also been observed occasionally in other enterococcal species (see Table 1 and 
below)(Zirakzadeh and Patel 2005; Werner et al., 2008a; Werner 2011). 
4. The van alphabet in Enterococcus spp. 
Non-susceptibility to glycopeptide antibiotics like vancomycin and teicoplanin is the key 
resistance characteristic in enterococci. Acquired resistance to vancomycin is mediated by  
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The image of the vanC cluster from naturally vancomycin-resistant E. gallinarum and E. casseliflavus were 
introduced for reasons of comparability. Arrows indicate genes and arrowheads show the direction of 
transcription. Colour codes represent functional groups: red, two-component regulatory system; yellow, 
core genes essential for resistance expression; grey, serine racemase; white, additional or unknown 
function. Arrow lengths are according to the size of the genes but are not drawn to scale. * denotes point 
mutations leading to constitutive expression of the VanD-type resistance. For further details see main text 
or references given there. PR and PH are promoters preceding vanR and vanH, respectively. TeR, gene 
associated with decreased teicoplanin susceptibility. For references see legend of Table 1.  
Fig. 1. Structure and composition of the vancomycin resistance clusters vanA-M (see also 
Table 1). Types vanA, vanB, vanD and vanM encode D-Ala-D-Lac mediated resistance; types 
vanC, vanE, vanL and vanG (also vanN, not shown) encode D-Ala-D-Ser mediated resistance 
(see text and Table for details)  
various mechanisms (types VanA/B/D/E/G/L/M/N; Table 1); the vanA and vanB 
resistance genotypes are by far the most prevalent worldwide. Isolates of E. gallinarum and 
E. casseliflavus (= E. flavescens) are naturally (intermediate-)resistant to vancomycin at low 
levels (MIC = 8 mg/L) by a so-called VanC-1/-2 type.  
4.1 The VanA resistance type  
The original vanA gene cluster contains nine genes which are arranged in a transposon 
structure (Arthur et al., 1993)(Fig. 1). It is flanked by two incomplete inverted repeats and 
possesses two coding sequences located at the left end (ORFs 1 and 2 not shown in Fig. 1). 
Their putative proteins show similarity with resolvases and transposases of various 
transposons or plasmids. The entire element is 10,981 bp and designated Tn1546, belonging 
to transposons of the Tn3-family. 
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Expression of VanA type vancomycin resistance in enterococci is inducible via a complex 
mechanism. The consequences of a prevented cell wall synthesis are sensed by an as yet still 
unknown mechanism via a membrane-associated, Tn1546-encoded protein VanS possessing 
a histidine kinase in its cytoplasmatic C-terminus. The histidine kinase function of the VanS 
protein is activated by autophosphorylation and the corresponding phosphate moiety is 
transferred to a cytoplasmic response regulator called VanR also encoded on Tn1546. 
Phosphorylated VanR functions as a transcriptional activator binding at two promoters PR 
and PH in the vanA resistance gene cluster (Arthur et al., 1997). This leads to the expression 
of two transcripts of genes that are arranged in an operon structure and that are transcribed 
unidirectional: the vanRS genes themselves and the gene cluster vanHAXYZ (Fig. 1). The 
proteins VanH, VanA and VanX possess essential functions for the expression of 
glycopeptide resistance whereas VanY encodes a D,D-carboxypeptidase contributing to 
elevated resistance levels and a VanZ protein of unknown function but contributing by an 
unknown mechanism to low-level teicoplanin resistance (Fig. 2)(Arthur and Quintiliani, Jr. 
2001). VanA type vancomycin resistance is mediated via an alternative pathway 
synthesizing cell wall precursors ending in D-Alanyl-D-Lactat (D-Ala-D-Lac) showing 
reduced glycopeptide binding and down-shifting of the regular cell wall synthesis by house-
keeping enzymes (Fig. 1)(Arthur and Quintiliani, Jr. 2001).  
Studies about characterizing the structure of vanA gene clusters in enterococci of different 
ecological and geographical sources displayed a great variety of point mutations, deletions 
(in/of non-essential genes), and insertions of additional DNA (mainly IS elements) leading 
to modified and fragmented Tn1546 structures. This can be demonstrated in a phylogenetic 
tree of relatedness exemplifying elements typically identified in US hospital VRE, poultry 
VRE, pig/human commensal VRE, etc. (Willems et al., 1999; Werner et al., 2006). Typing of 
vanA gene clusters allows elucidating ways of spread of vancomycin resistance either via 
clonal spread of VRE or via horizontal gene transfer between different enterococci (Park et 
al., 2007; Sletvold et al., 2010). 
 
Ddl, D-Ala:D-Ala ligase; adding enzyme is a synthetase; Penta, L-Ala-Ǆ-D-Glu-L-Lys-D-Ala-D-Ala; 
Pentadepsi, L-Ala-Ǆ-D-Glu-L-Lys-D-Ala-D-Lac; Tetra, L-Ala-Ǆ-D-Glu-L-Lys-D-Ala; Tri, L-Ala-Ǆ-D-Glu-
L-Lys. Penta, Tetra, Tri, Pentadepsi represent amino acid side chains linked to the enterococcal 
peptidoglycan disaccharide precursor N-acetyl-glucosamin-N-acetyl-muramic acid. Resistance enzymes 
encoded by the vanA cluster are shown in bold. [Figure adapted from (Courvalin 2006)]. 
Fig. 2. VanA-type glycopeptide resistance. Synthesis of an alternative, vancomycin-
resistant pentadepsipeptide peptidoglycan precursor in VanA-type resistant strains.  
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4.2 The VanB resistance type  
The typical VanB phenotype is characterized by inducible moderate vancomycin resistance 
levels (MICs of 8 - 64 mg/L) and teicoplanin susceptibility. vanB isolates with high-level 
vancomycin resistance have also been identified. Differences in the vanB gene were found 
and three different vanB ligase alleles were assigned which can be used for subtyping [vanB-
1/-2/-3; (Dahl et al., 2003; Werner et al., 2006)]. However, the different vanB genotypes did 
not correlate with the level of vancomycin resistance. Despite being slightly different in 
nucleotide composition, the vanB cluster types 1 to 3 all resemble the core structure of the 
vanA gene cluster (Fig. 1). Genes of related composition and function are arranged in a 
similar manner, an equivalent to vanZ is lacking and an additional gene vanW of unknown 
function was found. Genes encoding the two-component regulatory system vanRBSB are 
only distantly related to their Tn1546 counterparts and regulation of gene expression is 
different, because only vancomycin, but not teicoplanin, is an inducer of the vanB cluster. 
The entire transposon backbone of vanB clusters is different to vanA; distinct vanB cluster 
types are either flanked by certain IS elements or an integral part of larger mobile and/or 
conjugative elements that may be composed of several individual elements [Tn1547, Tn1549, 
Tn5382-like, Tnvamp; (Carias et al., 1998; Dahl and Sundsfjord 2003; Werner et al., 2006; 
Launay et al., 2006; Valdezate et al., 2009; Lopez et al., 2009)]. The conjugative vanB 
transposon Tn1549 or its backbone is widely prevalent among vanB type enterococci and 
related Gram-positive bacteria such as Clostridium spp. (see chapter 5;(Launay et al., 2006; 
Tsvetkova et al., 2010)). Conjugative transposons have been known for a long time in 
Enterococcus and Bacteroides and were lately also identified in Gram-negatives. They have an 
important function for a wide distribution of (resistance) genes across species and genus 
barriers and for genomic rearrangements in bacteria in general (Rice et al., 2005; Roberts and 
Mullany 2009; Rice et al., 2010; Roberts and Mullany 2011). 
Whereas teicoplanin does not induce VanB type resistance, constitutively resistant mutants 
quickly arose in vivo during therapy or in vitro after teicoplanin challenge (Baptista et al., 
1999; Kawalec et al., 2001a; Kawalec et al., 2001b; San Millan et al., 2009b). Accordingly, 
teicoplanin treatment is not recommended for eradicating VanB VRE infections despite a 
correspondingly suggestive diagnostic result (teicoplanin susceptibility).  
Expression via the VanB type two-component regulatory system VanRBSB is differently 
regulated in various Gram-positive hosts. Naturally occurring VanB type Streptococcus 
bovis/gallolyticus isolates retained the VanB phenotype inducible by vancomycin only (Poyart 
et al., 1997; Mevius et al., 1998). Genetic constructs of vanB cluster elements in a Bacillus 
subtilis background did not show an inducible phenotype since VanSB was active also 
without vancomycin addition (San Millan et al., 2009a). In addition, it was shown that the 
phosphorylated regulator VanRB-P was capable of binding to a number of promoter regions 
and thus controlling expression of genes commonly regulated by response regulators.  
4.3 The VanC resistance type  
The two motile species E. gallinarum and E. casseliflavus possess an intrinsic resistance to 
vancomycin at a low level designated VanC-1 and VanC-2, respectively. The corresponding 
vanC-type ligase gene possessed minor sequence diversity resulting in the two described 
subtypes vanC-1 and vanC-2 (Courvalin 2005; Courvalin 2006). The formerly third species E. 
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flavescens described as possessing a supposed vanC-3 gene was merged recently with the 
species E. casseliflavus (Naser et al., 2006b) thus leading to two subtypes of E. casseliflavus 
with slightly different vanC-2/-3 subtype variants. Recently, another subtype vanC-4 was 
described in another E. casseliflavus isolate with 93-95% nucleotide identity with vanC-2/-3 
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S, susceptible (no MIC given); 1 Acquisition of vanA, vanB or vanD genes in addition to vanC1/C2 genes 
– rare event; 2 subtypes exist (vanB1-3, vanD1-5, vanG1-2); 3 several strains exist with different 
teicoplanin MICs; 4 data from a presentation given by R. Leclercq, ESCMID conference on Enterococci, 
Barcelona/ES, 18.-20.11.2009. 
Table 1. Types of acquired vancomycin resistance in enterococci  
Nucleotide identity varied also along the other elements of the vanC-4 cluster with genes 
vanXYC, vanTC, vanRC, and vanSc showing 88-93 % identity with corresponding genes of the 
vanC-2/-3 cluster (see below and Fig. 1). VanC type resistance is mediated via a modified D-
Ala-D-Ser moiety similar to VanE/G/L/N types reaching also a similar low level of 
resistance only (Arias et al., 2000). All these resistance types require activity of a serine 
racemase converting L-Ser into D-Ser, the first one of these enzymes/genes was described in 
E. gallinarum (Arias et al., 1999). The vanC-1 gene cluster of E. gallinarum contains a ligase 
gene vanC-1, a combined D-Ala-D-Ala dipeptidase/carboxypeptidase vanXYC gene, a vanT 
racemase gene and two genes encoding a sensor kinase/response regular two-component 
regulatory system vanRC and vanSC (Reynolds et al., 1999; Reynolds and Courvalin 2005). 
The vanC-2 cluster in E. casseliflavus showed a composition similar to the vanC-1 cluster in E. 
gallinarum (Dutta and Reynolds 2002). Due to the different VanC resistance mechanism a 
vanH equivalent is functionally not required and missing. Initially it was thought that VanC 
type resistance was always constitutively expressed as a species-specific property. However, 
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E. casseliflavus expressed an inducible resistance phenotype which was detected several 
hours after induction in vitro (Dutta and Reynolds 2002). E. gallinarum isolates expressing an 
inducible and constitutive phenotypes were identified; mutational changes in the amino 
acid sequences of the corresponding sensor histidine kinases VanSC in constitutive and 
inducible strains were demonstrated (Panesso et al., 2005). Acquisition of mobile vanA, vanB 
and vanD gene clusters additional to the natural vanC-1/-2 cluster in E. 
gallinarum/casseliflavus may lead to high-level vancomycin resistance in these strains; 
however, their prevalence remains low (Foglia et al., 2003; Mammina et al., 2005; Haenni et 
al., 2009; Neves et al., 2009).  
4.4 The VanD resistance type 
The basic organization of the vanD operons, which are located exclusively on the 
chromosome, is similar to that of the vanA and vanB clusters (Casadewall and Courvalin 
1999; Boyd et al., 2000; Depardieu et al., 2003b; Depardieu et al., 2004; Boyd et al., 2004). 
Genes equivalent to vanZ or vanW are absent. The vanD resistance clusters appear as a 
remarkable example of how by certain mutational events regulatory networks adjust and 
finetune gene expression: VanD-type strains have negligible VanXD activity, an enzyme that 
normally shuts down synthesis of vancomycin-susceptible, housekeeping call wall precursors. 
This otherwise physiological drawback is compensated by an inactivated D-Ala-D-Ala ligase 
(deletions, point mutations, insertion) host enzyme, preventing synthesis of vancomycin-
susceptible precursors ending in D-Ala-D-Ala. However, vanD expression and corresponding 
essential cell wall precursor synthesis would still request induction by glycopeptides 
(vancomycin dependence). Consequently all investigated VanD type E. faecalis, E. faecium and 
E. avium strains show a constitutive resistance phenotype resulting from different mutations in 
the VanSD sensor or VanRD regulator. Another unusual feature of VanD-type strains is their 
only slightly diminished susceptibility to teicoplanin (Tab. 1) which cannot be explained on 
the basis of already known DNA sequence diversities. Due to different strategies in 
establishing those complex and highly regulated networks independently and via different 
routes five different vanD cluster types had arranged and were characterized so far (Boyd et 
al., 2000; Depardieu et al., 2004). Up to now, VanD-type resistance still is a rare van 
resistance type among enterococci but has been described in a VanC type E. gallinarum N04-
0414, too (Boyd et al., 2006b). In this strain the vancomycin resistance phenotype is 
constitutive but typical VanD strain features are lacking (mutations in vanSD linked to 
constitutive expression; shut-down of housekeeping D-Ala-D-Ala ligase activity, etc.). A 
vanD cluster was also described in E. raffinosus (Tanimoto et al., 2006). It showed almost 
identity to the vanD4 gene cluster of E. faecium 10/96A and expressed all features of typical 
VanD type resistance such as an inducible resistance phenotype based on VanSD mutations.  
Different VanD-type enterococci present a number of different combinations of mutations 
(mainly in VanSD) suggesting an independent development and convergent evolution 
(Depardieu et al., 2009). These various modifications also led to a wide range of resistance 
phenotypes with low to high-level vancomycin resistant strains (16-512 mg/L) and 
susceptibility (0,5 mg/L) and low to high-level resistance to teicoplanin (≤ 64 mg/L)(Tab. 1). 
Remarkably, VanD strain E. faecium BM4656 had a wildtype Ddl enzyme being the only 
VanD strain with a functional D-Ala-D-Ala ligase. In this strain, also enzymes VanXD and 
VanYD were active being essentiell for shutting down synthesis of glycopeptide-susceptible 
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cell wall precursors in a background of an active host Ddl enzyme for mediating 
vancomycin resistance (Fig. 3) (Depardieu et al., 2009).  
 
Ddl, D-alanine:D-alanine ligase; adding enzyme is a synthetase; Pentadepsi, L-Ala-Ǆ-D-Glu-L-Lys-D-Ala-
D-Lac; Tri, L-Ala-Ǆ-D-Glu-L-Lys. Tri and Pentadepsi represent amino acid side chains linked to the 
enterococcal peptidoglycan disaccharide precursor N-acetyl-glucosamin-N-acetyl-muramic acid. Resistance 
enzymes encoded by the vanD cluster are shown in bold. [Figure adapted from (Courvalin 2006)]. 
Fig. 3. VanD-type glycopeptide resistance. Synthesis of peptidoglycan precursors in a 
VanD-type resistant strain. Dependence on the presence of vancomycin in a background of 
reduced VanXD activity (VanXD) and a non-functional Ddl is compensated by mutations in 
VanRD or VanSD leading to a constitutive resistance phenotype (not demonstrated in details; 
see also main text and Fig. 2). 
4.5 The VanE resistance type  
Isolates representing a VanE resistance type were described in a few E. faecalis strains from 
Northern America and Australia (Fines et al., 1999; Abadia Patino et al., 2002; Boyd et al., 
2002; Abadia Patino et al., 2004). The vanE resistance cluster resembles structures of the 
vanC1 cluster naturally occurring in E. gallinarum (Fig. 2) and shows also highest similarities 
with the corresponding proteins. Therefore resistance is mediated by producing D-Ala-D-
Ser-terminated cell wall precursors (Tab. 1). Due to that and as compared to the VanC 
resistance type, VanE type vancomycin resistance requires a VanT racemase converting L-
Ser into D-Ser (Fines et al., 1999; Abadia Patino et al., 2002). VanE strains remain teicoplanin-
susceptible and show moderate to low levels of inducible vancomycin resistance. Despite 
this phenotype, sequence determination suggested a putative non-functional VanSE protein 
indicating cross-talk between the VanRE response regulator and other functional membrane-
located kinase activators. All five consecutive genes of the vanE gene cluster were 
cotranscribed from a single promoter (Abadia Patino et al., 2004). Downstream the vanE 
cluster in a single Canadian VanE-type E. faecalis an integrase gene is found, which may 
have been involved in the acquisition of this operon; however, when tested in vitro the vanE 
cluster was in all attempts not transferable (Boyd et al., 2002). Initially a van gene cluster 
designated vanE has been described in Paenibacillus popilliae showing 74-79 % protein 
sequence identity with the corresponding essential proteins VanH/A/X in vanA clusters 
(Patel et al., 2000; Patel 2000; Guardabassi et al., 2005; Guardabassi and Agerso 2006). This 
has later been renamed into vanF (see chapter 5).  
4.6 The VanG resistance type  
E. faecalis possessing a vanG cluster were low-level vancomycin-resistant and teicoplanin-
susceptible (McKessar et al., 2000; Depardieu et al., 2003a; Boyd et al., 2006a). Resistance is 
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mediated via inducible synthesis of D-Ala-D-Ser-terminated cell wall precursors. Only few 
isolates have been described and vanG gene clusters identified allow differentiation into two 
subtypes. The chromosomal vanG cluster consists of seven genes which according to its 
order and gene composition appear to be reassembled from different van operons (Fig. 1). In 
contrast to all the other van operons, the vanG cluster encodes three putative gene products 
with regulatory functions. Besides the common vanRG and vanSG determinants a vanUG gene 
encoding an additional putative transcriptional activator was identified (Depardieu et al., 
2003a; Boyd et al., 2006a). The vanY gene is present but a frame-shift mutation resulting in 
premature termination of the encoded protein accounted for the lack of disaccharide-
tetrapeptide prescursors in the cytoplasm (Depardieu et al., 2003a). VanG-type resistance 
was successfully transferred in vitro and acquisition of the vanG cluster was associated with 
a transfer of a 240 kb chromosomal fragment flanked by imperfect inverted repeats 
(Depardieu et al., 2003a). Crystallisation and X-ray analysis of the VanG D-Ala-D-Ser ligase 
in complex with ADP was described recently (Weber et al., 2009).  
4.7 The VanL resistance type  
A single E. faecalis isolate from Canada (N06-0364) expressed low level vancomycin 
resistance by a new mechanism called VanL (Boyd et al., 2008). The corresponding VanL 
gene mediates D-Ala-D-Ser ligation. The vanL gene cluster was similar in organization to the 
vanC operon, but the VanT serine racemase was encoded by two separate genes, vanTmL 
(membrane binding) and vanTrL (racemase) resembling the two functional domains of the 
otherwise combined vanT type racemase (Fig. 1)(Boyd et al., 2008). The putative VanL ligase 
exhibited 51 and 49% sequence identity to the VanE and VanC ligases, respectively. All 
attempts to transfer the vanL gene cluster in vitro failed. The E. faecalis isolate N06-0364 did 
not demonstrate plasmids assuming that the vanL gene cluster was chromosomally encoded.  
4.8 The VanM resistance type  
The vanM genotype was described in seven Chinese VRE isolates originating from a single 
hospital and revealing three different MLST (ST18, ST78, ST341) and five PFGE 
types/subtypes (Xu et al., 2010). A single VanM VRE was investigated in greater details. The 
translated sequence of VanM, the corresponding ligase, showed highest similarity to the 
VanA, the corresponding VanM gene product mediates ligation of the D-Ala-D-Lac peptide. 
The vanM gene cluster showed a gene arrangement similar to vanB and vanD with the D,D-
carboxypeptidase gene vanYM preceding the ligase gene (Fig. 1). VanM type resistance was 
transferable by conjugation in vitro and plasmid-located. VanM phenotype showed in vitro 
resistance against vancomycin and tecioplanin in six of seven isolates investigated (the 
single ST341 isolate was susceptible to teicoplanin).   
4.9 The vancomycin dependence phenotype  
Soon after the first appearance of vanA- and vanB-type VRE, strains with unusual resistance 
phenotypes were notified including constitutively resistant strains and even vancomycin-
dependent isolates of the species E. faecalis, E. faecium and E. avium (Woodford et al., 1994; 
Rosato et al., 1995; Sifaoui and Gutmann 1997). Features of in vitro selected strains were 
similar to variants identified from clinical cases mostly associated with long term 
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vancomycin treatment. In vancomycin-dependent VRE the housekeeping D-Ala-D-Ala 
ligase (ddl gene) is not functional due to modifications in the coding sequence (point 
mutations, deletions, insertions). Consequently depletion of D-Ala-D-Ala dipeptides leads 
to an impaired cell wall synthesis. The effect could be complemented by providing the 
missing D-Ala-D-Ala dipeptide (Sng et al., 1998a) or similar di- or depsipeptides. 
Vancomycin is capable of inducing the VanA or VanB type resistance and thus providing D-
Ala-D-Lac as the necessary substrate for a revived cell wall synthesis. These strains remain 
dependent on the inducing effect of vancomycin for an ongoing cell wall synthesis. 
Dependence on vancomycin could be circumvented by subsequent mutations targeting the 
two-component regulatory system of VanR and/or VanS. Mutations in the histidine kinase 
or the regulator may bypass the inducing property of the antimicrobial compound in 
leading to a constitutive resistance phenotype not requiring vancomycin anymore. This 
switch from inducible to constitutive vancomycin resistance phenotype may also appear 
independently from a previous vancomycin dependence phenotype (Sng et al., 1998b; 
Baptista et al., 1999). As described recently in a VanB type VRE, a mutation in the 
transcription terminator of the regulatory genes resulting in transcriptional readthrough of 
the resistance genes from the PRB promoter in the absence of vancomycin may also 
circumvent vancomycin dependence and lead to a constitutive phenotype (San Millan et al., 
2009b). Expression of vancomycin resistance comes along with a fitness burden under non-
selective conditions (in the absence of glycopeptides). Accordingly VRE with a constitutive 
phenotype are less competitive under non-selective conditions (Foucault et al., 2010).  
5. The van alphabet in non-enterococcal strains  
5.1 The van alphabet in intestinal and environmental bacteria and glycopeptide 
producers 
Prevalence studies revealed occurrence of different van genes like vanB, vanD and vanG in 
non-enterococcal, human intestinal colonizers of Clostridium spp., Ruminococcus spp. and 
others (Patel 2000; Stinear et al., 2001; Domingo et al., 2005; Ballard et al., 2005b; Domingo et 
al., 2007). One of these isolates was investigated further and a new, naturally vancomycin-
resistant species, Ruminococcus gauvreauii, was identified possessing a vanD gene cluster 
(Domingo et al., 2008). In strains of Clostridium symbiosum an entire vanB2 type Tn1549 
cluster was identified which was transferable in vitro and in vivo in the digestive tract of 
mice highlighting the important role that commensal, intestinal, non-enterococcal hosts may 
play for acquiring, preserving and distributing (vancomycin) resistance genes to nosocomial 
pathogens (Launay et al., 2006). The corresponding conjugative transposon Tn1549 encodes 
all necessary functions for a successful transfer of the element across species and genus 
barriers also demonstrating its potential to transfer vanB type vancomycin resistance from 
Enterococcus to other important nosocomial pathogens like Staphylococcus spp, C. difficile and 
others (Tsvetkova et al., 2010). A large number of the C. difficile genome of the multi-drug 
resistant, clinical strain 630 consisted of mobile, genetic elements (11%) including a tet(M)-
encoding self-conjugative transposon Tn5397 (Sebaihia et al., 2006). Conjugative transposons 
like Tn5397/Tn916 (and also Tn1549) are easily exchanged between members of different 
bacterial species and genera and are identified in a wide range of different, Gram-positive 
bacterial species capable of self-transfer and mobilisation of other, genetic elements (Roberts 
et al., 2001; Jasni et al., 2010; Roberts and Mullany 2011). C. difficile 630 also contained an 
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element with similarity to a vanG type cluster; however, neither this cluster was complete 
nor was the strain vancomycin-resistant (Sebaihia et al., 2006). Clostridium innocuum is 
naturally intermediate-resistant to vancomycin (MIC = 8 mg/L). The mechanism of 
resistance was investigated in strain NCIB 10674 and found to be related due to the activity 
of two chromosomally encoded Ddl ligases and a racemase allowing the synthesis of a 
peptidoglycan precursor terminating in D-Ser similar to VanC/E/G/L type vancomycin 
resistance (David et al., 2004).  
Certain vancomycin-resistant strains of fecal streptococci belonging to the Streptococcus bovis 
group (e.g., S. gallolyticus, S. lutetiensis) were found to contain vanA and vanB genes (Poyart 
et al., 1997; Mevius et al., 1998); however, these strains were not investigated in greater 
molecular details. Results of another study revealed that the entire vanB2 type Tn5397 
conjugative transposon from a S. lutetiensis donor was capable to transfer into E. faecium and 
E. faecalis recipients in a recA-independent manner (Dahl and Sundsfjord 2003).  
Strains of Paenibacillus popilliae and Rhodococcus spp. contain vanA/B-like resistance gene 
clusters originally called vanE in P. popilliae and later on designated vanF (Patel et al., 2000; 
Guardabassi et al., 2004; Guardabassi et al., 2005; Guardabassi and Agerso 2006). P. popilliae 
ATCC 14706 is high-level vancomycin-resistant and contained a gene cluster with vanYF and 
vanZF preceding the vanHFX co-transcribed gene cluster. Two genes encoding a two-
component regulatory system of the VanRS type were identified ca. 3kb upstream vanYF 
associated with an inducible VanF phenotype (Fraimow et al., 2005).  
A number of Lactobacillus, Pediococcus, Leuconostoc and Lactococcus species are naturally 
resistant to vancomycin. This is an intrinsic property of certain species and, as known so far, 
mainly linked to a modified cell wall synthesis mediated via alternative precursors, 
functionally similar but not linked to an acquisition of any van gene cluster (Goffin et al., 
2005). For instance , in Leuconostoc mesenteroides a Ddl enzyme with a residual D-Ala-D-Lac 
activity was identified allowing the production of vancomycin-resistant cell wall precursors 
(Kuzin et al., 2000). In Lactobacillus plantarum vancomycin resistance is also mediated via a 
species-specific Ddl ligase capable of synthesising D-Ala-D-Lac depsipeptides and, in 
addition, an intrinsic VanX-like D-Ala-D-Ala dipeptidase destroying vancomycin-
susceptible cell wall precursors (Deghorain et al., 2007).  
Certain soil bacteria produce glycopeptide antibiotics including vancomycin (Amycolatopsis 
orientalis) and teicoplanin (Actinoplanes teichomyceticus) as secondary metabolites. They 
prevent themselves from sensitivity against their own products by intrinsic resistance 
mechanisms similar but not identical to acquired resistance types in Enterococcus spp. 
(Marshall et al., 1997; Marshall et al., 1998; Patel 2000). It was speculated that enterococcal 
resistance genes originated from corresponding glycopeptide producers (Marshall et al., 
1998; Patel 2000); however, comparably weak amino acid and nucleotide similarities among 
key genes and proteins involved in the resistance mechanism and the comparably high % 
GC of the VanRS regulatory system in the glycopeptide producers Streptomyces toyocaensis 
and A. orientalis suggested that a possible exchange between glycopeptide producers and 
nosocomial pathogens having acquired resistance properties did not happen recently 
(Courvalin 2005).  
The anaerobic, Gram-positive, dehalogenating bacterium Desulfitobacterium hafniense Y51 
was vancomycin-resistant by an inducible resistance phenotype (Patel et al., 2000). The 
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strain contained a resistance Ddl enzyme with a preferred D-Ala-D-Lac ligase activity and a 
vancomycin resistance gene cluster showing a slightly different gene arrangement as 
compared with vanA/B clusters. The essential vanH homologue was missing in this cluster 
element; however, genome analysis of D. hafniense Y51 revealed at least four D-isomer-
specific 2-hydroxyacid dehydrogenase genes capable in situ to perform the relevant vanH-
type reaction. Nevertheless, the physiological role, the overall prevalence of this gene cluster 
and the phylogenetic relation to acquired resistance gene clusters in Enterococcus spp. 
remain unclear so far (Patel 2000). 
It is known that intestinal colonisation could precede subsequent infections with VRE 
(Donskey 2004). Screening patients at risk for a colonisation with VRE is an important 
indicator in preventing and controlling VRE infections and outbreaks (Zirakzadeh and Patel 
2006). Molecular assays provide certain advantages over microbiological tests in terms of 
time, sensitivity and accuracy. Prevalence of van genes, especially vanB in intestinal, non-
enterococcal species impairs performance of rapid, molecular screening assays targeting the 
corresponding resistance genes only (Stamper et al., 2007; Mak et al., 2009; Usacheva et al., 
2010). Results of a number of studies performed with various commercially available 
diagnostic assays in Northern America, Australia, Asia and different countries in Europe 
also revealed that vanB is generally prevalent among human intestinal colonizers and that 
this is not a specific property of human intestinal colonisers in certain parts of the world 
(Ballard et al., 2005a; Stamper et al., 2007; Mak et al., 2009; Usacheva et al., 2010; Lee et al., 
2010; Marner et al., 2011; Werner et al., 2011c).  
5.2 The vanA gene cluster in Staphylococcus aureus 
Vancomycin is the antibiotic of choice for treating MRSA infected patients. Insusceptibility 
to vancomycin associated with treatment failure is insofar a matter of serious concern. 
Various microbiological changes could lead to reduced susceptibility against vancomycin 
including increased cell wall thickness, activated cell wall synthesis and reduced autolysis. 
The former changes are based on a modified host gene expression of determinants involved 
in cell wall synthesis leading to a so-called “trapping effect” where more unlinked cell wall 
precursors are present being able to bind (more) vancomycin (“to trap” the drug)(Cui et al., 
2005; Werner et al., 2008c; Nannini et al., 2010). The Vancomycin intermediate-resistant 
phenotype (VISA) could be expressed homogeneously or only in a subset of investigated 
strains (1 of 105 cells = heterogeneous VISA - hVISA), the latter requires a sophisticated 
diagnostics via a population-based-analysis profiling (PAP)(Howden et al., 2010). VISA or 
hVISA phenotypes are not associated with (van) gene acquisition.  
Early in vitro studies demonstrated the capability of a transfer of the enterococcal VanA 
type resistance into S. aureus/MRSA rendering descendents as vancomycin- and oxacillin-
resistant (Noble et al., 1992). The first clinical vanA-mediated high-level vancomycin-
resistant MRSA (VRSA) was isolated from a dialysis patient in Michigan, USA (Weigel et al., 
2003; Chang et al., 2003). Since then, less than a dozen additional cases have been described, 
nine in the United States (Michigan [n= 7], New York and Pennsylvania) and each one in 
India and in Iran (the latter two were not confirmed elsewhere) (Sievert et al., 2008; Finks et 
al., 2009; Nannini et al., 2010).  
The US VRSA isolates showed high-level vancomycin resistance of >32 mg/L. All US 
patients affected by VRSA infections had a history of several underlying conditions and 
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accordingly, all of them were treated extensively with antibiotics including vancomycin and 
most of them were co-colonized with VRE, respectively. The US VRSA isolates exhibited the 
SmaI macrorestriction patterns USA100, SCCmecII and USA800, SCCmecIV and all isolates 
could be assigned to sequence type 5 by multilocus sequence typing (MLST). Typing of 
corresponding strains, their resistance plasmids and corresponding Tn1546-like vanA 
clusters revealed that the isolates were unique and had evolved separately (see next 
paragraph).  
From the first case patient a MRSA strain, a vanA-type E. faecalis and a vanA-type MRSA 
were isolated which allowed constructing a scenario where the MRSA received the vanA 
type resistance from the resistant co-colonising E. faecalis. This has been confirmed by 
molecular analysis of the corresponding vanA-type plasmids from related VRSA and MRSA 
isolates (Weigel et al., 2003; Clark et al., 2005; Zhu et al., 2008). The VRSA isolate contained a 
58 kb conjugative plasmid pLW1043, the MRSA a ca. 47 kb pAM829 plasmid and the VRE 
two plasmids of 45 and 95 kb. Restriction digestion revealed similar patterns for the 
pLW1043 and pAM829 plasmids but not for the E. faecalis plasmids (Weigel et al., 2003). 
pLW1043 was fully sequenced and revealed a Tn1546-like vanA cluster integrated between 
the blaZ (beta-lactamase) and the aacA-aphD (gentamicin resistance) regions. It showed a 
mosaic-like structure, but the backbone was similar to staphylococcal type pSK41 plasmids 
and different from typical enterococcal plasmids suggesting acquisition of the vanA cluster 
by a resident staphylococcal-type plasmid (Kwong et al., 2008; Weaver et al., 2009). 
Interestingly, majority of other VRSA and co-colonising VRE isolates contained inc18-type 
vanA plasmids investigated in a follow up study (Zhu et al., 2008). The inc18-type plasmids 
represent broad-host range plasmids widely prevalent among Gram-positive bacteria of 
different enterococcal, staphylococcal and streptococcal species (Weaver et al., 2009). 
Plasmids from three VRSA cases were sequenced [plasmids pWZ7140 (47,277 bp), pWZ909 
(42,602 bp), and pWZ1668 (48,365 bp)]. They were almost identical among each other and to 
a corresponding vanA plasmid from co-colonising E. faecalis strains revealing a possible 
direct transfer from an E. faecalis donor into MRSA (Zhu et al., 2008). Molecular studies with 
isogenic MRSA and VRSA isolates revealed that acquired VanA-type resistance was highly 
costly to the host, when induced (Foucault et al., 2009). In the absence of induction, the 
determined biological cost was minimal suggesting a serious potential for the dissemination 
of VRSA clinical isolates. 
An comparison of US VRSA isolates (Michigan VRSA, Pennsylvania VRSA) to the vanA-
type E. faecalis from the index patient, the possible donor of the resistance gene cluster for 
the Michigan VRSA, revealed interesting details on the resistance gene regulation and 
expression in different hosts (Perichon and Courvalin 2004). The Michigan VRSA was highly 
resistant to both glycopeptides, whereas the Pennsylvania VRSA displayed low-level 
resistance to vancomycin and reduced susceptibility to teicoplanin. Resistance genes were 
expressed at similarly high levels in the two VRSA and the vanA-type E. faecalis; however, 
resistance expression was notably delayed in the Pennsylvania strain. Resistance was lost at 
non-selective condition from the Pennsylvania VRSA. In contrast, it was stable in the 
Michigan VRSA and the VRE (Perichon and Courvalin 2004). Two Michigan VRSA isolates, 
designated VRSA-7 and VRSA-9 showed a vancomycin dependence phenotype. Molecular 
studies revealed a similar mechanism as known from enterococci with the corresponding 
resistance phenotype. VRSA-7 and VRSA-9 contained different mutations in the 
housekeeping D-Ala-D-Ala ligase leading to a decreased activity and dependence on the 
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vanA-type D-Ala-D-Lac ligase for an ongoing cell wall synthesis (Moubareck et al., 2009; 
Meziane-Cherif et al., 2010). Strikingly, peptidoglycan precursors ending in D-Ala-D-Lac are 
not processed by PBP2a, the oxacillin-resistant penicillin binding protein encoded by mecA 
and consequently the VRSA-7 and VRSA-9 were fully susceptible to oxacillin, despite the 
production of a wild-type PBP2a (Moubareck et al., 2009). This also means that the 
combination of a beta-lactam and a glycopeptide antibiotic shows a synergistic effect for 
VRSA in general (Perichon and Courvalin 2006). Comparison of the two vancomycin-
dependent VRSA isolates (VRSA-7/-9) indicated that the levels of vancomycin dependence 
and susceptibility to ǃ-lactams correlate with the degree of D-Ala-D-Ala ligase impairment 
(Meziane-Cherif et al., 2010). 
6. Prevalence of VRE among the hospital setting  
Modern molecular typing techniques (AFLP, MLVA, MLST)2 allow differentiating between 
commensal and hospital-associated/outbreak E. faecium isolates including vancomycin-
resistant and vancomycin-susceptible variants (Willems and Bonten 2007; Willems and van 
Schaik W. 2009). Genomic diversity is higher in commensal E. faecium isolates 
(animal/human) as compared to hospital strains types that especially show a predominance 
of a number of specific MLST or MLVA types (Werner et al., 2007b; Werner et al., 2011a). 
Results of a comparative genome-based study revealed a distinct composition of the 
accessory genome in hospital-associated E. faecium strains (Leavis et al., 2007). Results have 
been confirmed by recent comparative analyses of completely sequenced E. faecium genomes 
(van Schaik et al., 2010; Palmer et al., 2010). The current model predicts that spread of 
ampicillin-resistant, hospital-associated E. faecium strains is a pre-requisite for successful 
establishment of VRE and further dissemination of vancomycin resistance among the 
hospital E. faecium population in general (Willems and Bonten 2007; Galloway-Pena et al., 
2009; Willems and van Schaik W. 2009). To a larger or lesser extent, non-microbiological 
factors such as antibiotic consumption (particular classes and in general); “colonisation 
pressure”, “understaffing”, compliance with hand hygiene and other infection control 
measures also affect the role and number of enterococcal infections (Bonten et al., 1998; 
Cetinkaya et al., 2000; Murray 2000; Bonten et al., 2001; Panesso et al., 2010). Therefore, it 
might not come as a big surprise that despite having similar starting points and 
preconditions different countries experienced diverse trends in VRE prevalence. Already 
during the early and mid-1990s, epidemic clonal types of E. faecium were prevalent in 
hospitals in many countries, and this coincided in some European countries with a high 
prevalence of vancomycin resistance among E. faecium from animals and healthy volunteers 
linked to a widespread use of avoparcin as a growth promoter in commercial animal 
husbandry (Murray 1990; Murray 2000; Bonten et al., 2001; Panesso et al., 2010). However, 
VRE rates in clinical isolates increased in many countries and peaked only almost ten years 
later when glycopeptide resistance had already declined in the non-hospital reservoir. 
Retrospective epidemiological analyses in hospitals experiencing larger VRE outbreaks 
revealed that changes in specific procedures such as antibiotic policy, staffing, infection 
prevention and control regimes were, in some instances, significantly associated with 
increasing VRE rates, whereas in other settings this could not be shown. Increased VRE 
                                                 
2 AFLP, Amplified-fragment length polymorphism; MLVA, Multiple Locus Variable number of tandem 
repeat Analysis; MLST, Multi-Locus Sequence Typing 
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prevalence is partly associated with spread of single, distinct epidemic clones or types 
(Klare et al., 2005; Top et al., 2007; Bonora et al., 2007; Werner et al., 2007c; Valdezate et al., 
2009; Zhu et al., 2010; Johnson et al., 2010; Hsieh et al., 2010). In contrast, VRE outbreaks in 
single centres tend to be polyclonal suggesting a diverse population of hospital-acquired E. 
faecium strains and a highly mobile resistance determinant capable of spreading widely 
among suitable recipient strains (Yoo et al., 2006; Deplano et al., 2007; Kawalec et al., 2007; 
Borgmann et al., 2007; Werner et al., 2007c; Hsieh et al., 2009). Many facets of VRE and 
vancomycin resistance epidemiology are currently not fully understood and the question 
why vancomycin resistance is still mainly limited to E. faecium remains mainly unanswered 
(Garcia-Migura et al., 2007; Garcia-Migura et al., 2008; Werner et al., 2010b). 
The main prevalent genotypes of acquired vancomycin resistance in enterococci worldwide 
are vanA and to a lesser extent vanB. The reservoir for vanA/B gene clusters is mainly in E. 
faecium; vanA/B-type resistant E. faecalis remain rare all over the world. Countries 
experiencing problems with increasing or significant higher rates of VRE always report 
about vancomycin-resistant E. faecium. Infections with members of other enterococcal 
species remain rare although also outbreaks with vanA/B-type resistant E. faecalis, E. 
raffinosus or VanC-type E. gallinarum were reported (Foglia et al., 2003; Kawalec et al., 2007; 
Neves et al., 2009; Shirano et al., 2010). In conclusion, the problem of VRE is mainly an issue 
of vanA-type vancomycin-resistant E. faecium (see the following). 
6.1 Europe 
Several national and European surveillance systems collect data on vancomycin resistance 
in enterococci. In some countries mandatory VRE surveillance is already established, in 
others coverage for the general population or selected settings is rather limited and the 
available data do not allow reliable statistical analyses and in some countries data are 
completely lacking. The most successful European antibiotic resistance surveillance scheme 
is the European Antimicrobial Resistance Surveillance System/network (EARSS/EARS-
Net),3 which was established in 1998 and is now funded by the European Centre for Disease 
Prevention and Control ECDC. EARS-Net collects data on antibiotic resistances in indicator 
bacteria exclusively from invasive (bloodstream) infections currently covering Streptococcus 
pneumoniae, S. aureus, Escherichia coli, E. faecalis/E. faecium, Klebsiella pneumoniae and 
Pseudomonas aeruginosa. In 2008 over 900 microbiological laboratories serving more than 
1,500 hospitals from 33 countries provided susceptibility data from more than 700,000 
invasive isolates. Inter-country comparison of collected data in the given setting reveals 
some drawbacks and limitations (not discussed here, see EARS reports and website). 
Accordingly, simple comparisons of surveillance data over time and between countries or 
even within single countries should be done carefully (see also chapter 4 in the EARS 
Annual Report 2008)(EARSS 2009). VRE surveillance within Europe has recently been 
reviewed and the reader is referred to this paper for any further details (Werner et al., 
2008a). In the following only a short summary and, in addition, some new aspects to these 
previous reports are given.  
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VRE surveillance in the Nordic European countries, Norway, Denmark, Sweden, Finland 
and Iceland, is based on national public health programmes for containment of 
antimicrobial resistance, participation in EARS and in some countries case notification from 
laboratories and clinicians. The Nordic countries have traditionally had a low prevalence of 
antimicrobial resistance, and this is also true for VRE. Within the last years a recognisable 
reservoir of vancomycin resistance among animal enterococci was demonstrated despite the 
ban of using any antimicrobial growth promoter, especially avoparcin (Sorum et al., 2006; 
Nilsson et al., 2009a; Nilsson et al., 2009b). It is still unclear if and to what extent this 
reservoir influences the situation in the clinical setting. In Sweden, the situation has been 
stable with 18–53 cases of VRE infections and colonisations being reported annually 
between 2000 and 2007. However, the situation has changed rapidly with the predominant 
spread of a vanB E. faecium clone with 634 among 760 VRE cases described within a 20 
months’ period from 2007-2009 (Soderblom et al., 2010). General prevalence of VRE in a 
Swedish hospital during a post-outbreak situation was still low (Fang et al., 2010). 
There is no single comprehensive surveillance scheme for monitoring VRE infections in the 
United Kingdom (UK). However, bacteraemia caused by VRE is monitored by four 
complementary surveillance programmes, with varying degrees of coverage and 
participation (Werner et al., 2008a). Numbers of VRE cases from invasive infections and 
general prevalence of vancomycin resistance in enterococci from the clinical setting is 
comparably high in relation to other European countries. Given the tremendous activities 
and partial success in reducing the MRSA burden in UK hospitals one might expect that 
these measures also lead to a reduction of VRE bacteraemia cases. Rates of vancomycin 
resistance among invasive E. faecium isolates varied between 33% (2005), 18% (2006), 21% 
(2007), 28% (2008), 13% (2009) (data from EARS-Net). The Department of Health mandatory 
glycopeptide-resistant enterococcal bacteraemia reporting scheme collects the total number 
of VRE bacteraemias in England each year. A supposed reduction in bacteraemia cases in 
both surveillance schemes conflicts with a possible reporting bias of participating hospitals 
and laboratories and it has to be shown that the supposed trends will be stable for the 
coming years4. The British Society for Antimicrobial Chemotherapy (BSAC) Bacteraemia 
Surveillance Programme reports data until 2008; however, a specific trend cannot be 
specified for “E. faecium“ and “vancomycin resistance”5.  
Certain European countries (Netherlands, Denmark, Spain) showed a wide prevalence of 
hospital-associated clonal types of E. faecium but vancomycin resistance rates are still low 
(Oteo et al., 2007; Lester et al., 2008; Top et al., 2008b; Valdezate et al., 2009; Lester et al., 
2009). In other countries rates of VRE remain at a comparably high rate such as Ireland and 
Portugal5 (Novais et al., 2008; Morris-Downes et al., 2010). Decreasing rates were considered 
significant in countries like Italy, France, Israel and Greece; however, it has to be 
documented if these trends are indeed lasting and not biased by other, so far unknown 
factors (see EARS-Net data).  
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Molecular typing of clinical enterococci sent to the German Focal Laboratory for 
Enterococcus revealed a significant increase in the number of vanB-type E. faecium among 
vancomycin-resistant E. faecium prevalent in different German hospitals (2006: 53/302, 18%; 
2007: 65/249, 26%; 2008: 95/298, 32%; 2009: 157/333, 52%; (Klare et al., 2010)). Preliminary 
findings direct to a similar trend in other European countries like Sweden (Soderblom et al., 
2010; Fang et al., 2010). If this increased VanB-type prevalence is linked to a supposed 
reservoir of vanB among enterococcal or non-enterococcal intestinal colonizers (Stamper et 
al., 2007; Young et al., 2007; Graham et al., 2008; Usacheva et al., 2010; Bourdon et al., 2010; 
Werner et al., 2011c) or simply linked to an improved and better identification of low-level 
expressed VanB-type resistance (Pendle et al., 2008; Grabsch et al., 2008a; Grabsch et al., 
2008b; Stamper et al., 2010) in relation to a reduced breakpoint as defined by EUCAST 
(EUCAST Clinical Breakpoint Table v. 1.1 2010-04-27)6 remains to be elucidated in further 
studies.  
6.2 Northern America 
Canada and the USA illustrate two divergent scenarios concerning vancomycin resistance 
rates among enterococci. In Canada resistance rates are persistently low (Karlowsky et al., 
1999; Zhanel et al., 2000; Nichol et al., 2006; Zhanel et al., 2008a; Zhanel et al., 2010b). Results 
of a recent CANWARD study performed in 2008 among 10 participating Canadian hospitals 
revealed 3.1% VRE among 320 clinical enterococcal isolates (Zhanel et al., 2010b). All 10 VRE 
were vanA-type E. faecium. VRE prevalence among Canadian ICU patients is low as well; 
VRE accounted for <1% (n= 17/ 4133) of all isolates and 6.7% (n= 17/255) of enterococcal 
isolates, majority of them (88%) possessed vanA (Zhanel et al., 2008b). Despite the low 
prevalence of the more common vancomycin resistance genotypes, a number of new and 
still rare vancomycin resistance genotypes of the vanD, vanE, vanG and vanL classes were 
identified in Canadian enterococci (Boyd et al., 2000; Van Caeseele et al., 2001; Boyd et al., 
2002; Boyd et al., 2004; Boyd et al., 2006a; Boyd et al., 2008). 
In contrast to the situation in Canada, vancomycin resistance among clinical enterococci 
from US medical centres is highly prevalent. It is mainly encoded by vanA-type resistance 
widely prevalent among hospital-associated clonal types of E. faecium (Karlowsky et al., 
2004; Nichol et al., 2006). The rapid increase in vancomycin resistance among the E. faecium 
population in US hospitals in general and the intensive care setting especially after its first 
appearance within a 10 years’ time span is a dramatic example of a fast growing resistance 
problem that nowadays neither can be controlled nor prevented or reversed. The obvious 
coincidence of a number of unfortunate circumstances and factors from either side, the 
health care setting (e. g., delayed compliance with infection control and prevention 
strategies; permission of oral vancomycin use) and the bacteria themselves (e. g., rapid 
spread of hospital-associated epidemic clones; vancomycin resistance genes in a stable and 
transferable genetic background) may have led to such a scenario (Martone 1998; Nichol et 
al., 2006). The Surveillance Network (TSN) collects data on blood culture isolates from 
patients from 268 US hospitals. Data for 2002 revealed in 67% vancomycin resistance among 
altogether 1.285 E. faecium isolates whereas the same resistance characteristics still remained 
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rare with <5% among E. faecalis isolates (Karlowsky et al., 2004). Results of other studies 
revealed similar rates (Nichol et al., 2006; Deshpande et al., 2007). The overall situation is 
even impaired during the last years showing a rise in the total number of hospitalisations 
due to VRE infections (Ramsey and Zilberberg 2009). The Nationwide Inpatient Sample 
available through the Healthcare Costs and Utilization Project Website showed increased 
incidence of VRE infections from 3.2 to 6.5 between 2003 and 2006. An increased use of 
vancomycin to treat increasing numbers of MRSA and Clostridium difficile infections was one 
of the major drivers. 
6.3 Latin America 
In Latin America, prevalence of VRE is generally considered to be low with rates <5% 
among enterococci in general and before 2005 (Quinones Perez 2006); however, reliable data 
based on comprehensive studies or data sets were missing. Results of a recent SENTRY 
study revealed a recognizable change of vancomycin resistance rates among clinical 
enterococcal isolates from participating Latin American countries/hospitals increasing from 
5 to 15.5% within 6 years (between 2003 and 2008). The most significant increase was 
demonstrated for Brazil with VRE rates rising from 7 to 31% (Sader et al., 2009). Considering 
that the majority of enterococcal isolates is E. faecalis which mainly remained susceptible to 
vancomycin, the increase of vancomycin resistance among E. faecium isolates seems even 
more dramatic based on the numbers specified. A molecular characterization of 
prospectively collected 732 enterococcal isolates from 2006 to 2008 from 32 hospitals in 
Colombia, Ecuador, Peru and Venezuela revealed vancomycin resistance in 6% of all isolates 
(Panesso et al., 2010). Considering only isolates of E. faecium (n= 111) prevalence of 
vancomycin resistance ranged from 24 to 48%; however, sample size per country was quite 
limited and a sampling bias cannot be excluded. Nevertheless, all vancomycin-resistant E. 
faecium were of the vanA genotype and represented hospital-associated strain types as 
determined by MLST (ST17, ST18, ST203, ST280 and others). Tn5382-vanB2 encoded VanB 
type resistance was demonstrated to be linked to two epidemic clones; a ST201 E. faecalis 
and a ST64 E. faecium disseminated among 9 and 15 Chilean hospitals, respectively (Lopez et 
al., 2009).  
6.4 Asia, Australia and New Zealand  
VanB-type resistance is only highly prevalent in certain parts of the world, for instance, in 
Australia (Christiansen et al., 2004; Pearman 2006; Worth et al., 2008; Pendle et al., 2008; 
Johnson et al., 2010) or Singapore (Koh et al., 2006; Koh et al., 2009) where vanB-type 
vancomycin resistance among clinical E. faecium is more prevalent than the vanA-type. The 
reason(s) for this remain unknown and are not linked to a supposed larger reservoir of the 
vanB cluster in commensal intestinal colonizers (Padiglione et al., 2000), rates of which were 
similar in Australian, US-American and European studies (Stamper et al., 2007; Graham et 
al., 2008; Grabsch et al., 2008b; Bourdon et al., 2010; Werner et al., 2011c). A larger reservoir 
of vanB-type resistance in isolates from commercial animal farming associated with an 
avoparcin use is unlikely; avoparcin use was ceased in Australia in 2000 and Singapore has 
no significant agriculture at all thus excluding a distinct animal vanB-type VRE reservoir 
(see chapter 7). However, community carriage linked to a consumption of imported and 
contaminated food cannot be excluded. Studies performed in New Zealand described a 
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supposed dissemination of vanA-type resistance among E. faecalis strains rather then E. 
faecium in a background of generally low level of vancomycin resistance (Manson et al., 
2003a; Manson et al., 2003b). VRE epidemiology in other Australasian countries reflects a 
similar scenario as in Europe or Northern America with vanA-type resistance highly 
prevalent among E. faecium. Several studies performed during outbreaks in Taiwanese 
hospitals revealed a preferred prevalence of (hospital-associated) vanA-type vancomycin-
resistant E. faecium strains (Hsieh et al., 2009; Hsieh et al., 2010). In South-Korean hospitals 
(and outside hospitals) vanA-genotype (VanB phenotype) E. faecium were widely prevalent 
(Ko et al., 2005; Shin et al., 2006; Park et al., 2008). Recent reports from China revealed also a 
preferred prevalence of vanA-type vancomycin resistance among clinical VRE (Zheng et al., 
2007a; Zheng et al., 2007b; Zhu et al., 2009). 
7. Vancomycin resistance among enterococci from farm animals, feedstuff 
and non-hospitalized humans and the environment 
Surveillance of antimicrobial resistance among enterococci as commensal colonizers of food-
producing animals became prominent during the early and mid 1990ies. At this time 
scientific and public awareness arose due to the argument that use of antimicrobial growth 
promoters, focused on the glycopeptide avoparcin, added to the feed of food animals in sub-
inhibitory concentrations is capable of selecting antibiotic-resistant bacteria; here 
glycopeptide/vancomycin-resistant enterococci. Large studies were initiated when higher 
numbers of VRE were suspiciously found in environmental samples without any known 
reservoir in or link to use of glycopeptides in human medicine (Klare et al., 1993; Torres et 
al., 1994). Soon after, avoparcin, another glycopeptide class antibiotic used in animal 
husbandry as a feed additive (growth promoter) was identified to select VRE in the animal 
setting (Bates et al., 1994; Klare et al., 1995a; Klare et al., 1995b; Bates 1997). Consequently, 
meat samples from commercially raised animals were highly contaminated with VRE 
including samples of pork, beef, chicken and turkey (Klare et al., 1995a; Klare et al., 1995b; 
Schouten et al., 1997; Klein et al., 1998; Simonsen et al., 1998; Kruse et al., 1999). Samples 
from organic or private farms of smaller sizes that did not use avoparcin or feed additives at 
all were free of VRE (Klare et al., 1995b; Klare and Witte 1998). Following the food chain, 
VRE reached humans and were capable of colonizing the intestines of healthy people; in 
contrast, a small study in vegetarians showed no detectable VRE counts (Schouten et al., 
1997; Van Den Bogaard et al., 1997; Stobberingh et al., 1999). Similar studies were performed 
all over Europe and data have already been reviewed in previous papers and book chapters 
and are thus not discussed in greater details here (Woodford et al., 1998; Klare and Witte 
1998; Aarestrup et al., 2000b; Bonten et al., 2001; Klare et al., 2003). In countries within the 
EU, avoparcin was abandoned in Norway and Denmark in 1995, Germany 1996 and in the 
remaining EU countries in 1997. Studies performed in some European countries soon after 
identified a reduced prevalence of VRE, their numbers dropped qualitatively and 
quantitatively in samples from commercial animal farms, food samples and following the 
food chain in humans of the general population (Klare et al., 1999). However, studies from 
Denmark and Norway showed that other antimicrobial growth promoters may lead to a co-
selection phenomenon and reduced VRE numbers were only documentable when other 
growth promoters like macrolides (spiramycin, tylosin) were also banned. The reason was a 
genetic linkage of both resistance determinants erm(B) and vanA on similar plasmids 
(Aarestrup 2000; Borgen et al., 2002). Based on the precautionary principle the European 
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Commission postponed the further use of four antimicrobial growth promoters with a 
supposed link (same antibiotic class) to antibiotics used in human medicine in 1998. This 
decision was confirmed in 2003 specifying the phasing out of all antimicrobial growth 
promoters within the EU [Regulation (EC) No. 1831/2003 on additives for use in animal 
nutrition]. However, VRE counts did not drop to zero. Studies in animal farms performed 
several years after the ban of several growth promoters including avoparcin revealed a 
permanent reservoir of VRE (Borgen et al., 2000; Borgen et al., 2001; Ghidan et al., 2008). 
Recent studies performed in Swedish animal farms still highlighted a considerable reservoir 
of VRE (Nilsson et al., 2009b). Sweden banned avoparcin and other growth promoters 
already in 1986 and VRE prevalence among the clinical setting as well as the general 
population was and still is very low but somehow widely found in sewage (Sahlstrom et al., 
2009). Phenotypic and genotypic characterization of the sewage VRE identified for the 
majority of them (a) species E. faecium and (b) the vanB-type. PFGE analysis revealed 
different strains prevalent over the study period. This finding is especially noticeable since a 
few years later rates of VanB-type E. faecium increased in certain Swedish hospitals 
(Soderblom et al., 2010; Fang et al., 2010). 
Outside Europe similar scenarios of VRE epidemiology were described. In Korea, VRE were 
still prevalent in livestock samples four years after banning avoparcin (Lim et al., 2006). VRE 
were isolated from 17% of the chicken samples (n= 57 strains from 342 meat samples) and 
2% of the pig samples (4 from 214 fecal samples) whereas no VRE were isolated from 110 
bovine samples. All the 61 VRE isolates were vanA-type E. faecium. A study performed in 
Japan three years after the ban of avoparcin (1997) did not identify any VRE among 515 
fresh faecal samples from 178 beef cattle, 179 pig and 158 broiler chicken farms representing 
all 47 Japanese prefectures (Kojima et al., 2010) whereas in 1996, one year before the ban, 3% 
(8/263) of enterococci tested were vancomycin-resistant (Yoshimura et al., 1998). However, 
in these two studies it was only screened for enterococci in general and subsequently 
resistances were determined. So it cannot be ruled out that samples contained VRE but at 
lower numbers then statistically recognizable with the described non-selective screening 
strategy. Avoparcin use was banned in Taiwan in 2000. A nationwide surveillance was 
initiated to study VRE prevalence on chicken farms from 2000 to 2003 (Lauderdale et al., 
2007). VRE were still identified, but counts dropped in a quantitative manner, only 8.8% (n= 
7/80) of the chicken farms surveyed harboured VRE in 2003 compared with 25% (15/60) in 
2000. Interestingly, majority were vancomycin-resistant E. faecalis (see below). This reflects a 
somehow different VRE epidemiology than in the rest of the world; similar to Australia 
where vanB-type E. faecium and vanA-type E. faecalis predominate (Worth et al., 2008; 
Johnson et al., 2010). In Australia, the general scenario appears to be different; a larger 
reservoir of VRE outside the clinical setting could not be identified despite an ongoing high 
use of avoparcin. For instance, prevalence rates of VRE in the general population were 
extremely low (0,2%), the two identified VRE among 1085 community specimens were vanB-
type E. faecium (Padiglione et al., 2000).  
In the US, avoparcin has never been used as a feed additive, a reservoir for VRE outside the 
clinical setting could not be identified when screening samples from various animal farms, 
meat, environmental sources and stool samples from healthy people during this time 
(Coque et al., 1996; McDonald et al., 1997; Martone 1998). However, situation changed the 
last years and vancomycin resistance was prevalent among 6 of 55 pig samples investigated 
in 2008 (Donabedian et al., 2010). 
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8. Localization and spread of vanA- and vanB-type resistance 
Vancomycin resistance in animal, human commensal and environmental sources is mostly 
encoded by vanA-type resistance clusters and its reservoir is in isolates of E. faecium; thus it 
reflects the same situation as in the clinical setting in most parts of the world. Exchange of 
resistant strains among different ecosystems is less probable due to the supposed ecovar 
association, especially among hospital-associated E. faecium strains (see chapter 5), although 
dissemination across host barriers of vancomycin- and multi-resistant enterococci was 
described anecdotally, especially for the less strongly host-adapted E. faecalis strains 
(Manson et al., 2003a; Manson et al., 2003b; Manson et al., 2004; Agerso et al., 2008; Larsen et 
al., 2010; Hammerum et al., 2010; Freitas et al., 2011a). Vancomycin resistance among 
enterococci most probably spreads via a dissemination of mobile genetic elements of 
variants of the vanA-type element Tn1546 mostly located on mobilizable or conjugative 
plasmids (Sletvold et al., 2007; Novais et al., 2008; Sletvold et al., 2008; Freitas et al., 2009; 
Rosvoll et al., 2009; Sletvold et al., 2010; Laverde Gomez et al., 2011; Werner et al., 2011b; 
Freitas et al., 2011b). In vitro transfer of vanA plasmids has been determined in a number of 
studies (Werner et al., 1997; van den Braak et al., 1998; Werner et al., 2010b) and transfer in 
vivo in digestive tracts of animals and human volunteers was also shown (Moubareck et al., 
2003; Lester et al., 2006; Lester and Hammerum 2010). Transfer rates under natural 
conditions may be higher than determined in vitro (Dahl et al., 2007). 
Molecular studies revealed a tremendous number of deletions, insertions, and modifications 
of the original Tn1546-like structure in different not epidemiologically linked VRE leading 
to a wide diversity of various Tn1546 subtypes (van den Braak et al., 1998; Willems et al., 
1999; Huh et al., 2004; Werner et al., 2006; Lim et al., 2006; Yoo et al., 2006). Despite its high 
diversity, identical cluster types were identified among clinical human and animal 
commensal and environmental strains suggesting a common reservoir and exchange of its 
mobile elements via conjugative plasmids or as part of larger mobile genomic islands in 
European, Asian and Australian studies (van den Braak et al., 1998; Jensen et al., 1998; 
Willems et al., 1999; Werner et al., 2006; Jung et al., 2007). Garcia-Migura and co-workers 
identified a hot spot for integration of Tn1546-like elements and it could be speculated if this 
integration site is more prevalent among plasmids and is the reason for the preferred 
prevalence of vanA clusters on specific plasmids (Garcia-Migura et al., 2008). Results of a 
recent study about horizontal transferability of vanA plasmids among enterococci, other 
lactic acid bacteria and bifidobacteria revealed a preferred transfer into and a possible host 
restriction within the species E. faecium (Werner et al., 2010b). In contrast, vanB-type 
elements preferably integrate into the chromosome, but are mobile as part of integrative and 
conjugative elements ICE (Paulsen et al., 2003; Hegstad et al., 2010). Occasionally vanB 
resides on (transferable) plasmids (Rice et al., 1998; Zheng et al., 2009); as noticed recently 
associated with larger VanB-type VRE outbreaks (Sivertsen et al., 2011; Bjorkeng et al., 2011). 
Many surveillance studies failed to recognize a considerable reservoir of vanB among 
enterococcal colonizers in animals and humans, whereas recent real-time based studies 
targeting vanB or improved methods of detection revealed a considerable reservoir among 
intestinal colonizers, maybe also non-enterococcal bacteria (see above). In general, the 
supposed low expression of vancomycin resistance among vanB strains may have lead to an 
underestimation of its general prevalence, since in many screening studies comparably high 
vancomycin concentrations were used to select VRE (Poole et al., 2005; Hershberger et al., 
2005). Rates of clinical vanB-type VRE are increasing, at least in some European countries 
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during last years (Johnson et al., 2010; Soderblom et al., 2010; Bourdon et al., 2011) and a link 
to a supposed reservoir outside the clinical setting, for instance, among mammal intestinal 
colonizers is discussed also in areas where vanB-type vancomycin resistance is more 
prevalent (Christiansen et al., 2004; Johnson et al., 2010). 
9. Genereal conclusion  
Vancomycin resistance in enterococci has established as an important health care problem 
worldwide. Eight genotypes of acquired vancomycin resistance in enterococci are known. 
The vanA-type resistance encoded by transposon Tn1546 and Tn1546-derived elements is 
the most prevalent resistance determinant followed by vanB-type clusters which are mainly 
part of integrative and conjugative elements (ICE) mostly residing within the chromosome. 
The main van genotype reservoir is in E. faecium. Prevalence of VRE among the clinical 
setting varies in different parts of the world. Their increased incidence is linked to 
characteristic predisposing factors in affected patients but also to the bacteria themselves. 
The latter concerns a preferred spread of hospital-associated strain types among health care 
settings. These strains differ from commensal strains by their core genomes (different MLST 
types and clonal complexes) and an additional genomic content including specific 
(resistance) plasmids. However, countries and institutions having similar pre-conditions 
may experience different developments and changes in VRE prevalence are multifactorial 
and cannot be simply addressed to or predicted from specific factors and circumstances. 
VRE and their resistance determinants are still prevalent among commercial animal 
husbandry despite the glycopeptide avoparcin and other antimicrobial substances were 
banned for growth promotion in many parts of the world. Their role to feed the 
(vancomycin) resistance gene pool of hospital-associated strain types remains to be 
elucidated in further studies.  
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